Pharmaceuticals 2010, 3(4), 1225-1231; doi:10.3390/ph3041225
Review

Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma

Department of Human Anatomy and Histology, University of Bari Medical School, Piazza G. Cesare, 11, Policlinico 70124, Bari, Italy
Received: 9 March 2010; in revised form: 21 April 2010 / Accepted: 22 April 2010 / Published: 22 April 2010
(This article belongs to the Special Issue Protein Kinase Inhibitors)
PDF Full-text Download PDF Full-Text [169 KB, uploaded 22 April 2010 09:08 CEST]
Abstract: Tyrosine kinase inhibitors are a new class of anticancer drugs, that are capable of directly interacting with the catalytic site of the target enzyme and thereby inhibiting catalysis. Therapeutically useful tyrosine kinase inhibitors are not specific for a single tyrosine kinase, but rather they are selective against a limited number of tyrosine kinases. The success of imatinib-mesylate (Gleevec®) for the treatment of patients with chronic myeloid leukemia has opened a intensive search for new small molecular compounds able to target other protein tyrosine kinases involved in the malignant transformation. This review article is focused on the use of tyrosine kinase inhibitors as antiangiogenic molecules in the treatment of multiple myeloma.
Keywords: angiogenesis; antiangiogenesis; multiple myeloma; tyrosine kinase inhibitors

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Ribatti, D. Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma. Pharmaceuticals 2010, 3, 1225-1231.

AMA Style

Ribatti D. Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma. Pharmaceuticals. 2010; 3(4):1225-1231.

Chicago/Turabian Style

Ribatti, Domenico. 2010. "Tyrosine Kinase Inhibitors as Antiangiogenic Drugs in Multiple Myeloma." Pharmaceuticals 3, no. 4: 1225-1231.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert